ArticleDiabetology & metabolic syndrome2024

Lipid-lowering drugs and inflammatory bowel disease's risk: a drug-target Mendelian randomization study.

Jiaxi Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.